{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:33:47Z","timestamp":1790573627785,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":1073,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.7861\/clinmed.2021-0232","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T16:55:31Z","timestamp":1621270531000},"page":"162-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immunobullous disease"],"prefix":"10.1016","volume":"21","author":[{"given":"Thomas J","family":"Tull","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Benton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.7861\/clinmed.2021-0232_bib1","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/0092-8674(91)90360-B","article-title":"Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion","volume":"67","author":"Amagai","year":"1991","journal-title":"Cell"},{"key":"10.7861\/clinmed.2021-0232_bib2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaci.2020.02.013","article-title":"Autoimmune bullous skin diseases, pemphigus and pemphigoid","volume":"145","author":"Egami","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.7861\/clinmed.2021-0232_bib3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jid.2018.07.042","article-title":"Incidence and mortality of pemphigus in France","volume":"139","author":"Jelti","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.7861\/clinmed.2021-0232_bib4","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/jid.2014.430","article-title":"IgE anti-LJM11 sand fly salivary antigen may herald the onset of fogo selvagem in endemic Brazilian regions","volume":"135","author":"Qian","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.7861\/clinmed.2021-0232_bib5","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.oraloncology.2003.09.020","article-title":"Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations","volume":"40","author":"Kaplan","year":"2004","journal-title":"Oral Oncol"},{"key":"10.7861\/clinmed.2021-0232_bib6","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/bjd.15930","article-title":"British Association of Dermatologists\u2019 guidelines for the management of pemphigus vulgaris 2017","volume":"177","author":"Harman","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.7861\/clinmed.2021-0232_bib7","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.7861\/clinmed.2021-0232_bib8","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jamadermatol.2014.1939","article-title":"Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris","volume":"150","author":"Ellebrecht","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.7861\/clinmed.2021-0232_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.7861\/clinmed.2021-0232_bib10","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fmed.2018.00220","article-title":"The growing incidence of bullous pemphigoid: overview and potential explanations","volume":"5","author":"Kridin","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.7861\/clinmed.2021-0232_bib11","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/exd.13401","article-title":"Neurological and psychiatric associations in bullous pemphigoid-more than skin deep?","volume":"26","author":"Forsti","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.7861\/clinmed.2021-0232_bib12","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients","volume":"154","author":"Kridin","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.7861\/clinmed.2021-0232_bib13","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","article-title":"Autoantibody Profile Differentiates between inflammatory and noninflammatory bullous pemphigoid","volume":"136","author":"Izumi","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.7861\/clinmed.2021-0232_bib14","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1365-2133.2012.11108.x","article-title":"Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort","volume":"167","author":"della Torre","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.7861\/clinmed.2021-0232_bib15","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/bjd.12072","article-title":"British Association of Dermatologists\u2019 guidelines for the management of bullous pemphigoid 2012","volume":"167","author":"Venning","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.7861\/clinmed.2021-0232_bib16","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet"},{"key":"10.7861\/clinmed.2021-0232_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/07853890.2016.1222450","article-title":"Dermatitis herpetiformis: a cutaneous manifestation of coeliac disease","volume":"49","author":"Collin","year":"2017","journal-title":"Ann Med"},{"key":"10.7861\/clinmed.2021-0232_bib18","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/ced.13992","article-title":"Dermatitis herpetiformis","volume":"44","author":"Salmi","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"10.7861\/clinmed.2021-0232_bib19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2133.1996.tb01496.x","article-title":"Protective effect of gluten-free diet against development of lymphoma in dermatitis herpetiformis","volume":"135","author":"Lewis","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.7861\/clinmed.2021-0232_bib20","doi-asserted-by":"crossref","first-page":"826","DOI":"10.2340\/00015555-2184","article-title":"Dermatitis herpetiformis refractory to gluten-free dietary treatment","volume":"96","author":"Hervonen","year":"2016","journal-title":"Acta Derm Venereol"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824031257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824031257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.7861\/clinmed.2021-0232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T08:48:24Z","timestamp":1744447704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211824031257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1470211824031257"],"URL":"https:\/\/doi.org\/10.7861\/clinmed.2021-0232","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunobullous disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.7861\/clinmed.2021-0232","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 Royal College of Physicians 2021. All rights reserved.","name":"copyright","label":"Copyright"}]}}